Nexalin Technology (NXL) Stock: Buy, Sell, or Hold?
NXL - Nexalin Technology, Inc. Common Stock
$4.82
-0.05 (-1.03%)
▼
5d:
-10.07%
30d:
+1255.84%
90d:
+920.11%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When NXL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NXL is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NXL is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NXL is currently trading at $4.82, which is considered extended relative to its 30-day fair value range of $-0.45 to $4.60.
Technical Outlook: Technically, NXL is in a strong downtrend. Immediate support is located at $0.25, while resistance sits at $7.69.
Market Sentiment: NXL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+1144.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NXL is in a strong downtrend. Immediate support is located at $0.25, while resistance sits at $7.69.
Market Sentiment: NXL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+1144.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.45 -
$4.60
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1144.8% below Wall St target ($60.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.45 -
$4.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.25
Resistance Level
$7.69
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.52
Wall Street Target
$60.00
(+1144.8%)
Revenue Growth (YoY)
-82.8%
Share & Embed Analysis
Last updated: September 13, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NXL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$62 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$376 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
